Englewood Cliffs, NJ, April 22, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has unanimously voted to uplist to the NASDAQ. Eric Weisblum, CEO, stated “Silo Pharma is proud to announce that we intend to begin the application process to list on…
